Pallidonigroluysian atrophy (PNLA) is a rare neurodegenerative disease that is pathologically defined by severe neuronal loss in the globus pallidus, substantia nigra, and subthalamic nucleus. In this article, we present
evaluate the insulin treatment in the morphology and expression of genes related to muscular atrophy of young Wistar rats after burn injury. After approval by CEUAUNIFESP (4857080514), 64 male Wistar ... gastrocnemius…
ecstasy. Results: Present case helps to understand common neurobiological mechanism behind psychosis and brain atrophy, and risk factors such as ADHD and ecstasy abuse. Conclusion: More research in this area
AIREN criteria and 135 patients were with other dementia subgroups. In MRI ratings, global atrophy (GA) and white matter hyperintensity (WMH) scores were significantly higher in VaD group ... medial temporal atrophy…
defined by the United Kingdom Department of Health: neovascular AMD (nAMD) and geographic atrophy (GA). GA can develop after nAMD as well. There is recent evidence of the development
double positive, CD4+ single positive and CD8+ single positive cells. Thymic atrophy, i.e. the loss in the number of thymocytes, occurs during aging, stress and infections. Indeed, thymic atrophy ... upon infection with…
study was designed to quantify the association between long-term PPI administration and gastric atrophy. Methods: A computerized search of PubMed was conducted to identify studies using the keywords (proton ... pump…
Objective: Brain herniation is a deadly dislocation, while atrophy is a reduction of the brain tissue. Although they seem isolated conditions, the current study reveals that the last is actually ... literature search…
increased the levels of myogenic proteins, such as MyHC and myogenin, and decreased the atrophy-related protein, atrogin-1 in cisplatin-treated C2C12 myotubes in vitro. Moreover, cisplatin-induced mitochondria
total intracranial volume (only structure) (p < 0.01; FWE corrected, cluster-extent 20 voxels). GM atrophy in both anterior (lobule I-IV) and posterior cerebellum (lobule VI, VIII ... showed significant higher DC in the…
subjects with MCI the VITACOG trial showed that B-vitamin treatment reduced the brain atrophy rate and slowed cognitive decline. We now show that these effects of B-vitamins ... interaction (P = 0.024) between B-vitamin…
Spinal Muscular Atrophy (SMA) is a devastating inherited disorder characterized by progressive loss of motor activity, failure of neuromuscular synapses and muscle weakness. Genetic cause of SMA is mutation
with the worst visual prognosis. This disease is reflected by an optic atrophy responsible of blindness, transient or permanent depending on the causal genetic mutation. Patient presents a sequential ... disease related…
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by deletion or mutation within the survival motor neuron 1 (SMN1) gene, leading to progressive limb and trunk muscle ... weakness…
Background: Childhood spinal muscular atrophy (SMA) is a common autosomal recessive disorder caused by mutations of the survival motor neuron 1 (SMN 1) gene, leading to progressive muscle weakness
ASPH which drives Notch. Objective. Experiments were designed to determine if alcohol-related WM atrophy was linked to inhibition of ASPH and Notch. Methods. Adult Long Evans rats were ... Results. Ethanol caused…
Posterior Cortical Atrophy (PCA), also called Benson’s syndrome, is a neurodegenerative disease characterized by a progressive occipital and parietal dysfunction, including visuospatial and visuoperceptual disorders…
Multiple system atrophy (MSA) is a sporadic neurodegenerative disease among adults, which can be characterized by autonomic nerve dysfunction, Parkinsonism, ataxia and pyramidal tract dysfunction, or overlapped symptoms
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases. Survival motor neuron1 (SMN1) is the SMA disease-determining gene. We examined the molecular basis
relationship between dysphagia and activities of daily living (ADL) in patients with multiple system atrophy (MSA), and to characterize dysphagia in patients with the cerebellar (MSA-C) and parkinsonian
deacetylase inhibitor that can increase the Survival Motor Neuron (SMN) level in Spinal Muscular Atrophy (SMA) patients and anticipated to be an effective therapeutic agent for SMA. Patient description
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.